As of June 30, 2025, CervoMed (CRVO) had approximately $33.5 million in cash, cash equivalents and marketable securities, as compared to $38.9 million as of December 31, 2024. Based on its current operating plan, CervoMed believes its cash, cash equivalents and marketable securities on hand as of June 30, 2025, along with remaining funds to be received from the Company’s grant from the NIA, will enable the Company to fund its planned operating expenses and capital expenditure requirements into the third quarter of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed Shares Business and Financial Updates Online
- CervoMed price target raised to $27 from $21 at Canaccord
- CervoMed’s Promising Clinical Trial Data and Strategic Focus Boost Buy Rating and Price Target
- CervoMed Announces Positive Phase 2b Trial Results
- CervoMed announces 32-week data from Extension phase of Phase 2b RewinD-LB